½ÃÀ庸°í¼­
»óǰÄÚµå
1447639

°ñÀÌ½ÄÆí ½ÃÀå : Àç·á À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµ - ¼¼°è ¿¹Ãø(2024-2032³â)

Bone Graft Substitutes Market-By Material Type [Allograft (DBM), Synthetic (Polymer, Ceramics, Composites)], Application (Spinal Fusion, Dental, Joint Reconstruction, Foot & Ankle, Craniomaxillofacial, Long Bone), End-use-Global Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 160 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ °ñÀÌ½ÄÆí ½ÃÀå ±Ô¸ð´Â 2024-2032³â CAGR 6.6%¸¦ ±â·ÏÇÕ´Ï´Ù. °ñÀ̽ÄÀº ¿Ü»ó ȯÀÚÀÇ »À Àç»ý°ú ȸº¹À» µ½´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Çõ½ÅÀûÀÎ »ýü Àç·á ¹× ÇÕ¼º ´ëüÀç¿Í °°Àº ÀÇ·á ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº °ñÀÌ½Ä ¼Ö·ç¼ÇÀÇ È¿°ú¿Í °¡¿ë¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ¿Ü»ó ȯÀÚÀÇ ¿ä±¸¸¦ ÃæÁ·ÇÏ°í ¼ö¼ú °á°ú¸¦ °³¼±ÇÏ´Â ¾÷°èÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 5¿ù ·Î¾â ¹ÙÀÌ¿À·ÎÁ÷½º(Royal Biologics)´Â ¹ÙÀÌ¿À-·¹ÀÎ(Bio-Reign) 3D °ñÀÌ½ÄÆíÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº À̽Ľà ¹æ»ç¼± Åõ°ú¼ºÀ» °®µµ·Ï ¼³°èµÈ ½ÅÁ¦Ç°ÀÔ´Ï´Ù.

°ñ ÀÌ½Ä ½ÃÀåÀº Àç·á À¯Çü, ¿ëµµ, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªÀ¸·Î ³ª´¹´Ï´Ù.

Àç·á À¯Çüº°·Î´Â ÇÕ¼º°ñ À̽ÄÀç°¡ 2032³â±îÁö ¿¬Æò±Õ 7%ÀÇ ³ôÀº ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â Á¢±Ù¼º, ºñ¿ë È¿À²¼º, Áúº´ ÀüÆÄ À§Çè °¨¼Ò¿Í °°Àº ÇÕ¼º °ñ À̽ÄÀçÀÇ ÀåÁ¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¼¼¶ó¹Í°ú Æú¸®¸Ó¸¦ Æ÷ÇÔÇÑ ÇÕ¼º °ñÀÌ½ÄÆíÀº »À Àç»ýÀ» ÃËÁøÇϱâ À§ÇØ Ãµ¿¬ »À¿Í À¯»çÇÑ Æ¯¼ºÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Á¤Çü¿Ü°ú ¹× Ä¡°ú ¼ö¼ú¿¡¼­ ÇÕ¼º Àç·áÀÇ »ç¿ë Áõ°¡¿Í Çõ½ÅÀûÀÌ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº °ñÀÌ½ÄÆí¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Ä¡°ú¿ë °ñÀÌ½ÄÆí ½ÃÀåÀº Ä¡°ú ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í Ä¡°ú ÀÓÇöõÆ® ¹× Ä¡°ú ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2024-2032³â 7.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °ñÀÌ½ÄÆíÀº ÀÓÇöõÆ® ½Ä¸³ ¹× Ä¡ÁÖ Ä¡·á¸¦ À§ÇÑ »À Àç»ýÀ» µ½´Â Ä¡°ú ¿ëµµ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä¡°ú ±â¼ú ¹× Àç·áÀÇ ¹ßÀüÀº ÀÌ·¯ÇÑ ´ëüǰÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±¸°­ °Ç°­°ú ½É¹Ì¼º¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ä¡°ú¿ë Á¦Ç° äÅÃÀº ´õ¿í ±ÞÁõÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ñÀÌ½Ä ´ëüÀç »ê¾÷ ±Ô¸ð´Â 2024-2032³â ¿¬Æò±Õ 7.6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ³ëÀÎ Àα¸ Áõ°¡, Á¤Çü¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡, ÷´Ü ÀÇ·á ±â¼ú äÅà Áõ°¡ µî¿¡ ±âÀÎÇÕ´Ï´Ù. Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡´Â ȯÀÚ Àα¸°¡ ¸¹°í ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, °ñÀÌ½Ä ´ëüǰ ¼ö¿ä¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àç»ýÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ºñ¿ë È¿À²ÀûÀÎ °ñÀÌ½ÄÆíÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁö¸é¼­ ÀÌ Áö¿ª ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • Á¤Çü¿Ü°ú ÁúȯÀÇ Áõ°¡
      • °ñÀÌ½ÄÆíÀÇ ±â¼úÀû Áøº¸
      • ¼ö¼ú °Ç¼öÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • °ñÀÌ½Ä ¼ö¼úÀÇ °íºñ¿ë
      • ÇÑÁ¤µÈ »óȯ Á¤Ã¥
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®
  • »óȯ ½Ã³ª¸®¿À
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¼ÒÀç À¯Çüº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • µ¿Á¾ÀÌ½ÄÆí
    • Żȸ°ñ¸ÅÆ®¸¯½º(DBM)
    • ±âŸ µ¿Á¾ÀÌ½ÄÆí
  • ÇÕ¼º
    • Æú¸®¸Ó
    • ¼¼¶ó¹Í
    • º¹ÇÕÀç·á
    • °ñÇü¼º ´Ü¹éÁú(BMP)

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿ëµµº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ôÃß °íÁ¤
  • Ä¡°ú
  • °üÀý Àç°Ç
  • Á·°üÀý
  • µÎ°³¾Ç¾È¸é
  • Àå°ñ

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ »ç¿ëº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Àü¹® Ŭ¸®´Ð
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2018-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • AlloSource
  • Baxter International Inc.
  • DePuy Synthes(Johnson & Johnson Inc.)
  • Geistlich Pharma AG
  • Medtronic plc
  • NuVasive, Inc.
  • Orthofix US LLC.
  • OST Laboratories
  • Smith+Nephew
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
KSA 24.03.26

Global Bone Graft Substitutes Market size will record 6.6% CAGR from 2024 to 2032, attributed to the increasing number of trauma cases resulting in bone fractures and defects. Bone graft substitutes play a crucial role in aiding bone regeneration and repair in trauma patients. Rapid advancements in medical technology, such as innovative biomaterials and synthetic substitutes are enhancing the effectiveness and availability of bone grafting solutions. This combination of factors will propel the industry growth in meeting the needs of trauma patients and improving surgical outcomes. For instance, in May 2023, Royal Biologics introduced the Bio-Reign 3D bone graft substitute, a novel product in its line designed to be radiolucent upon implantation.

The bone graft substitutes market is divided into material type, application, end-use, and region.

Based on material type, the synthetic segment will achieve a noteworthy revenue share, depicting 7% CAGR through 2032, fueled by advantages of synthetic substitutes, such as availability, cost-effectiveness, and reduced risk of disease transmission. Synthetic bone grafts, including ceramics and polymers, offer properties that closely mimic natural bone for promoting bone regeneration. Additionally, the increasing adoption of synthetic materials in orthopedic and dental procedures along with the rising demand for innovative and biocompatible bone graft substitutes will add to the segment growth.

Bone graft substitutes market from the dental application segment will garner 7.3% CAGR from 2024 to 2032, due to the increasing prevalence of dental disorders and the rising demand for dental implants and procedures. Bone graft substitutes play a vital role in dental applications in aiding in bone regeneration for implant placements and periodontal treatments. Moreover, advancements in dental technology and materials are fueling the adoption of these substitutes. With the growing emphasis on oral health and aesthetics, the product adoption will further soar in dental applications.

Asia Pacific bone graft substitutes industry size will demonstrate 7.6% CAGR from 2024 to 2032, driven by the expanding geriatric population, rising prevalence of orthopedic conditions, and the increasing adoption of advanced medical technologies. Countries like China and India are significantly contributing to the demand for bone graft substitutes with their large patient population and improved healthcare infrastructure. Additionally, the growing focus on regenerative medicine and the higher availability of cost-effective bone graft substitutes will further bolster the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of orthopedic disorders
      • 3.2.1.2 Technological advancements in bone graft materials
      • 3.2.1.3 Rising number of surgical procedures
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of bone graft procedures
      • 3.2.2.2 Limited reimbursement policies
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Reimbursement scenario
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Material Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Allograft
    • 5.2.1 Demineralized bone matrix (DBM)
    • 5.2.2 Other allografts
  • 5.3 Synthetic
    • 5.3.1 Polymers
    • 5.3.2 Ceramics
    • 5.3.3 Composites
    • 5.3.4 Bone morphogenic proteins (BMP)

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Spinal fusion
  • 6.3 Dental
  • 6.4 Joint reconstruction
  • 6.5 Foot & ankle
  • 6.6 Craniomaxillofacial
  • 6.7 Long bone

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Specialty clinics
  • 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 AlloSource
  • 9.2 Baxter International Inc.
  • 9.3 DePuy Synthes (Johnson & Johnson Inc.)
  • 9.4 Geistlich Pharma AG
  • 9.5 Medtronic plc
  • 9.6 NuVasive, Inc.
  • 9.7 Orthofix US LLC.
  • 9.8 OST Laboratories
  • 9.9 Smith + Nephew
  • 9.10 Stryker Corporation
  • 9.11 Zimmer Biomet Holdings, Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦